• uniQure Gene Therapy AMT-060 Shows Long-term Efficacy in Hemophilia B Patients
  • Fitusiran Clinical Development Among 2018 Corporate Goals, Alnylam Pharmaceuticals Says
  • You Are Always Welcomed Back to the Community
  • Clinical Trial Testing CB 2679d in Hemophilia B Patients is Shortened
  • Catalyst Biosciences Starts Phase 2/3 Trial of Therapy to Prevent Hemophilia Bleeding Episodes
  • Software to Help Personalize ADVATE Treatment of Hemophilia A Receives FDA Clearance
  • Clinical Study in Ireland Aims to Improve Care for Hemophilia Patients by Using Personalized Approaches
  • Tips for Managing Your Bleeding Disorder in the New Year
  • Tremeau and FDA Agree on Phase 3 Plan to Test Rofecoxib in Hemophilia Joint Pain
  • FDA Lifts Clinical Hold on Investigational Therapy Fitusiran
  • Hemophilia and the Holidays: When the Hospital Calls
  • New Analysis Confirms FDA-approved Alprolix Benefits in Patients with Severe Hemophilia B